A Study to Assess the Tolerability of a Single Dose of Gefapixant (AF-219/MK-7264) in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Clinical trial NCT02477709 · COMPLETED
Trial details
- NCT number
- NCT02477709
- Sponsor
- Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2015-07-20
- Primary completion
- 2015-08-07
- Enrollment
- 6
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.